The FDA's new path, the status of animal testing, and other biotech news from The Readout STAT Summit research HHS Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home Newsletter The Readout Drugmakers guard IP more tightly amid China competition The FDA’s new path, the status of animal…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. We’ve got some news and commentary from our Breakthrough Summit West to get into today.
The need-to-know this morning
- Parabilis Medicines has filed to go public under the symbol PBLS.
Former FDA commissioner David Kessler said he has “great confidence” in Kyle Diamantas, the new interim FDA chief after Marty Makary left the agency.
Continue to STAT+ to read the full story…
US Pharma Marketing